Waking at night to void can have a profound impact on productivity

Abstract

number of incontinence and micturition episodes/day. Analyses of covariance were used to assess the effects of mirabegron on baseline-week 12 changes in WPAI. Longitudinal generalized estimating equations and Pearson correlation coefficients were used to assess associations between WPAI and OAB severity. Subgroup analyses were conducted for patients who discontinued prior OAB medication due to insufficient efficacy. RESULTS: Among the study sample (total N=858, employed N=394), mirabegron-treated patients experienced significantly greater improvement in TAI (12.3% vs. 6.7%, p<0.01) and greater but nonsignificant improvements in absenteeism (0.2% vs.-0.5%), presenteeism (8.6% vs. 6.0%), and TWPI (8.2% vs. 5.8%) than placebo-treated patients at week 12.. Based on the association analyses, 2.0%, 1.4% and 1.4% increases per additional incontinence episode and, 1.2%, 1.1% and 1.1% increases per additional micturition episode were observed in TAI, presenteeism, and TWPI respectively (p<0.01). Baseline-week 12 change in TAI was significantly correlated with changes in OAB severity (incontinence: r=0.17, micturition: r=0.11; p<0.01). Similar trends were observed in the patient-subgroup with prior treatment nonresponse. CONCLUSIONS: Patients treated with mirabegron experience significantly reduced total activity impairment. Impairments in work productivity and activity outcomes are associated with OAB symptom severity, suggesting that treatments that improve symptom severity may also improve productivity impairment.

How frequent night-time bathroom visits can negatively impact sleep, well-being and productivity: Examining the associations between nocturia, well-being and economic outcomes in a working-age population

“…Undertaking a systematic review of the literature, the authors identify research that utilises the WPAI measure. Drawing on data from three nocturia-related studies (Andersson et al, 2013;Biliotti et al, 2014;Kobelt et al, 2003), Miller et al (2016) find that nocturia increases overall work impairment from anywhere between 10 and 39 per cent, reporting a large range of work-impairment estimates varying, in part, based on which relevant covariates were included. When compared to the magnitude of work impairment of other conditions, nocturia has a similar impact on productivity as overactive bladder (11-41%), gastroesophageal reflux disease (6-42%), asthma/allergies (6-40%), chronic obstructive pulmonary disease (19-42%), sleep problems (12-37%), depression (15-43%) and gout (20-37%).…”